Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alphamab Oncology ( (HK:9966) ) has provided an announcement.
Alphamab Oncology announced the completion of a share placing by its controlling shareholder, involving 14,600,000 shares, which represents approximately 1.51% of the company’s issued share capital. This transaction, executed at HK$8.05 per share, adjusts the shareholding distribution, with the Vendor now holding 31.0% of shares. This move is likely to impact the company’s market positioning and shareholder dynamics.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company focused on the research, development, and commercialization of innovative cancer therapies. The company operates within the pharmaceutical industry, primarily targeting oncology treatments to address unmet medical needs.
Average Trading Volume: 4,371,905
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.04B
For an in-depth examination of 9966 stock, go to TipRanks’ Stock Analysis page.